Press release

Siemens Healthineers raises outlook for fiscal year 2021 after outstanding first quarter

Published on February 1, 2021

Siemens Healthineers AG today announced its results for the first quarter of fiscal year 2021 that ended December 31, 2020.

Q1 Fiscal Year 2021

  • Excellent start into the fiscal year with 13.3% comparable revenue growth from the prior-year quarter
  • Equipment book-to-bill ratio at a very good 1.16
  • Outstanding comparable revenue growth of 23.5% in Diagnostics – significant revenue contribution from rapid COVID-19 anti-gen tests in EMEA and return to growth in the core business
  • High comparable revenue growth of 9.3% in Imaging and 6.3% in Advanced Therapies; very good development in EMEA and Asia, Australia
  • High profitability: Adjusted EBIT margin increases by 550 bps year-over-year to 19.1%
  • Adjusted basic earnings per share up to €0.49, from €0.36 in the prior-year quarter
  • Free cash flow by far more than doubled year-over-year to €668 million 

Updated Outlook for Fiscal Year 2021

  • Comparable revenue growth of 8% to 12% expected (previously 5% to 8%)
  • Adjusted basic earnings per share between €1.63 and €1.82 (previously €1.58 to €1.72)

Link to the related press feature

Siemens Healthineers 2021

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at